Mutational Landscape in Myeloproliferative Neoplasms: Implications on Prognosis and Clinical Management
The diagnosis and management of patients with myeloproliferative neoplasms (MPN) has evolved since the identification of “driver” mutations, namely JAK2, CALR, and MPL mutations. Health care providers are challenged to stay abreast of new developments in the field that may help inform clinical decision-making.
Category
  • Myeloproliferative Neoplasms
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recommendations for Managing Adults with Histiocytic Neoplasms: New NCCN Guidelines
That patients’ signs and symptoms are often nonspecific can lead to delays in diagnosis and treatment of histiocytic disorders, and ambiguous cases should be evaluated at centers of expertise. Although challenging, it is important that clinicians remain current with advances in the management of these disorders.
Category
  • Hematologic Malignancies
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
General Principles of Biomarker Testing: When Should Broad Genomic Profiling Be Performed and What Do Different Tests Offer?
Biomarker testing is increasingly being utilized in oncology practice. Practitioners need to know the types of genetic alterations that can be detected, the technologies that can be used to detect these alterations, and the limitations of those techniques in order to ensure that their patients can be appropriately diagnosed, monitored, and matched with targeted therapies or recommended for clinical trials.
Category
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
General Principles of Test Interpretations: What Results are Actionable and How to Advise Patients About Results?
Oncologists need to be able to understand and interpret the increasingly vast and complex results that are obtained from genomic testing in order to ensure that appropriate testing is done and that the results can be effectively communicated with their patients.
Category
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Biomarkers in Solid Tumors: What’s on the Horizon?
Biomarker testing in oncology is an area of rapid growth. Practitioners need to be aware of new techniques that are being developed for detection of genomic alterations, and should also be aware of ongoing clinical trials that use novel trial designs and methodology for development of biomarker tests and targeted therapies.
Category
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Head and Neck Cancers, Version 1.2022
These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of HPV-positive oropharynx cancer and ongoing research in this area.
Category
  • Head and Neck Cancers
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Hematopoietic Growth Factors, Version 1.2022
The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA).
Category
  • Myeloid Growth Factors
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Lung Cancer Screening, Version 1.2022
The NCCN Guidelines for Lung Cancer Screening recommend criteria for selecting individuals for screening and provide recommendations for evaluation and follow-up of lung nodules found during initial and subsequent screening. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Lung Cancer Screening.
Category
  • Lung Cancers
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Bladder Cancer, Version 2.2022
These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle-invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.
Category
  • Bladder Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Ovarian Cancer, Version 3.2022
These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.
Category
  • Ovarian Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation